Martha Carlin is a microbiome researcher who got into science the hard way—when her husband was diagnosed with Parkinson’s disease at age 44. With a background in business operations and systems analysis, not biology, she refused to accept the fragmented, siloed explanations medicine offered. Instead, she started asking different questions: What systems broke down? What upstream disruptions may have caused this? And can we restore function at the biological root?
That investigation led her deep into microbiome science, microbial ecology, and the physics of living systems—years before gut health became a wellness buzzword. What began as a personal search for answers turned into more than a decade of rigorous research and eventually led her to speak on stages at TEDx Boulder and the White House Microbiome Initiative, where she helped shape early national conversations on the microbiome’s role in human and environmental health.
Martha founded The BioCollective, one of the world’s first independent, IRB-approved human microbiome research initiatives and stool biobanks. Under her leadership, The BioCollective secured a $1.2 million grant from the National Institutes of Health to develop TruMatrix—the first standardized human microbiome sample created to support emerging microbiome research globally. TruMatrix enables researchers worldwide to validate methods and calibrate instruments, supporting more robust microbiome research.
She also founded BiotiQuest, a consumer and practitioner brand that translates cutting-edge microbiome science into targeted, clinically validated, probiotics with real results. But BiotiQuest doesn’t formulate like everyone else. Instead of dumping high counts of random strains into a capsule and hoping for the best, Martha designs microbial guilds—coordinated teams of bacteria created to restore specific biological functions. These formulations target metabolic flexibility, immune resilience, sleep and circadian signaling, cardiovascular health, stress response, and gut recovery after antibiotics.
BiotiQuest’s approach is built on a proprietary BioFlux metabolic model, a systems-based framework that maps how microbial communities interact and influence our metabolism. That innovation led to Sugar Shift receiving a U.S. patent in 2024—a rare achievement for a natural product, and a validation of Martha’s fundamentally different approach to probiotic design.
But Parkinson’s remains her deepest work—the condition that started it all. In collaboration with physicist Dr. Barry Ninham, Martha is exploring the physical and structural foundations of chronic disease, investigating how the body’s signaling architecture and biophysical systems may hold answers that conventional biochemical models have missed.
At BEYOND, Martha reveals how microbiome systems thinking expands the frontier of biohacking—offering a biology-first framework for metabolic health, performance, and longevity that works with your body’s innate intelligence, not against it. Come ready to rethink what’s possible.
